TuisGS71 • FRA
add
GSK plc
Vorige sluiting
€24,79
Dagwisseling
€24,55 - €24,99
Jaarwisseling
€14,68 - €26,02
Markkapitalisasie
121,83 mjd USD
Gemiddelde volume
1,48 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
LON
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (GBP) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 8,62 mjd | 6,17% |
Bedryfskoste | 4,57 mjd | -0,28% |
Netto inkomste | 636,00 m | 53,62% |
Netto winsgrens | 7,38 | 44,71% |
Wins per aandeel | — | — |
EBITDA | 2,50 mjd | 35,38% |
Effektiewe belastingkoers | 23,47% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (GBP) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 3,41 mjd | -21,27% |
Totale bates | 61,12 mjd | 2,78% |
Totale aanspreeklikheid | 45,16 mjd | -2,62% |
Totale ekwiteit | 15,96 mjd | — |
Uitstaande aandele | 4,01 mjd | — |
Prys om te bespreek | 6,08 | — |
Opbrengs op bates | 5,87% | — |
Opbrengs op kapitaal | 10,70% | — |
Kontantvloei
Netto kontantverandering
| (GBP) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 636,00 m | 53,62% |
Kontant van bedrywe | 2,28 mjd | -2,19% |
Kontant van beleggings | -933,00 m | 16,62% |
Kontant van finansiering | -856,00 m | -1,66% |
Netto kontantverandering | 448,00 m | 19,47% |
Beskikbare kontantvloei | 1,15 mjd | -49,69% |
Meer oor
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Gestig
27 Des. 2000
Webwerf
Werknemers
68 629